Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

SORA Division, Faculty of Medicine, Sir Alexander Fleming Building, Imperial College London, South Kensington, London, United Kingdom.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2009; 106(34):14728-33. DOI: 10.1073/pnas.0904489106
Source: PubMed

ABSTRACT We provide a demonstration in humans of the principle of pharmacometabonomics by showing a clear connection between an individual's metabolic phenotype, in the form of a predose urinary metabolite profile, and the metabolic fate of a standard dose of the widely used analgesic acetaminophen. Predose and postdose urinary metabolite profiles were determined by (1)H NMR spectroscopy. The predose spectra were statistically analyzed in relation to drug metabolite excretion to detect predose biomarkers of drug fate and a human-gut microbiome cometabolite predictor was identified. Thus, we found that individuals having high predose urinary levels of p-cresol sulfate had low postdose urinary ratios of acetaminophen sulfate to acetaminophen glucuronide. We conclude that, in individuals with high bacterially mediated p-cresol generation, competitive O-sulfonation of p-cresol reduces the effective systemic capacity to sulfonate acetaminophen. Given that acetaminophen is such a widely used and seemingly well-understood drug, this finding provides a clear demonstration of the immense potential and power of the pharmacometabonomic approach. However, we expect many other sulfonation reactions to be similarly affected by competition with p-cresol and our finding also has important implications for certain diseases as well as for the variable responses induced by many different drugs and xenobiotics. We propose that assessing the effects of microbiome activity should be an integral part of pharmaceutical development and of personalized health care. Furthermore, we envisage that gut bacterial populations might be deliberately manipulated to improve drug efficacy and to reduce adverse drug reactions.

Download full-text


Available from: Jeremy K Nicholson, Jul 21, 2014
  • Source
    • "The gut microbiome (the collective genomes of the gut microbes) encodes 3.3 million non-redundant genes and is 150 times larger than the human gene complement, with most of these genes having unknown functions (Qin et al., 2010). Recent evidences suggested that gut microbiota affect many aspects of host physiology, including the diet, vitamin production, drug metabolism, disease pathogenesis, and the regulation of the immune system (Xu et al., 2013), as well as the metabolism of pharmaceuticals, heavy metals, and organic chemicals (Breton et al., 2013; Clayton et al., 2009). The composition of the gut microbiota and the number of microorganisms differed in dependence on local environmental conditions (Frick and Autenrieth, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neochamaejasmin A, isolated from Stellera chamaejasme L., has been widely used in China. Gut microbiota represent the first barrier against xenobiotics. This study aimed to evaluate the effects of subchronic exposure to neochamaejasmin A on the composition of gut microbiota. We found that neochamaejasmin A altered 21 OTUs in female rats and 46 OTUs in male rats. Among these OTUs, OTU86, OTU338 and OTU482 were shared in neochamaejasmin A-fed groups in both genders, implying that neochamaejasmin A might promote the growth of these three genera. In contrast, little or no effect on 226 OTUs was observed at all doses in both genders, suggesting their resistance to neochamaejasmin A. These findings could help improve our understanding of the health effects of neochamaejasmin A and provide an example of the risk assessment of pharmaceuticals or food contaminants on the gut microbiota composition. Copyright © 2015 Elsevier B.V. All rights reserved.
    Environmental Toxicology and Pharmacology 03/2015; 39(2). DOI:10.1016/j.etap.2015.03.005 · 1.86 Impact Factor
    • "It is best to test new biomarkers under multiple different scenarios to determine the domain of applicability of the biomarker (Altar et al. 2008; Matheis et al. 2011). This review will cover biomarkers of APAP-induced liver injury that were discovered in omics nonclinical studies (Chen et al. 2008; Clayton et al. 2009; Coen et al. 2003; Reilly et al. 2001; Stamper et al. 2011; Sun et al. 2009; van Swelm et al. 2012; Yang et al. 2012b) or multiple omics nonclinical studies (Coen et al. 2004; Prot et al. 2011; Ruepp et al. 2002; Sun et al. 2012), whether these biomarkers went through analytical biomarker verification and whether these biomarkers have been observed in clinical studies (Bhattacharyya et al. 2014a, b; Fannin et al. 2010; Yang et al. 2015). This review will provide the status of APAP protein adducts and systems biology omics biomarkers (miRNAs, protein biomarkers and metabolite biomarkers ) of APAP liver injury in the clinical setting. "
    Toxicology Letters 09/2014; 229:S99-S100. DOI:10.1016/j.toxlet.2014.06.367 · 3.36 Impact Factor
  • Source
    • "ug – microbiome interactions gained momentum after the HMP was launched . Although over 60 such inter - actions have been documented , the underlying molecular mechanisms and genetic bases for those interactions remain largely unknown , and only very recently have some of those mechanisms unfolded for a few drugs , for example , acet - aminophen ( Clayton et al . , 2009 ) , digoxin ( Haiser et al . , 2013 ) , and cyclophosphamide ( Viaud et al . , 2013 ) — reviewed in Table 2 . With more microbiomes sequenced across the human population , it is expected that more inter - actions will be discovered and more mechanisms will be identified . The emerging interest in this branch of pharma - cogenomics , whi"
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The Human Microbiome Project (HMP) is a global initiative undertaken to identify and characterize the collection of human-associated microorganisms at multiple anatomic sites (skin, mouth, nose, colon, vagina), and to determine how intra-individual and inter-individual alterations in the microbiome influence human health, immunity, and different disease states. In this review article, we summarize the key findings and applications of the HMP that may impact pharmacology and personalized therapeutics. We propose a microbiome cloud model, reflecting the temporal and spatial uncertainty of defining an individual's microbiome composition, with examples of how intra-individual variations (such as age and mode of delivery) shape the microbiome structure. Additionally, we discuss how this microbiome cloud concept explains the difficulty to define a core human microbiome and to classify individuals according to their biome types. Detailed examples are presented on microbiome changes related to colorectal cancer, antibiotic administration, and pharmacomicrobiomics, or drug-microbiome interactions, highlighting how an improved understanding of the human microbiome, and alterations thereof, may lead to the development of novel therapeutic agents, the modification of antibiotic policies and implementation, and improved health outcomes. Finally, the prospects of a collaborative computational microbiome research initiative in Africa are discussed.
    Omics: a journal of integrative biology 05/2014; DOI:10.1089/omi.2014.0018 · 2.73 Impact Factor
Show more